Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8221163 | International Journal of Radiation Oncology*Biology*Physics | 2013 | 7 Pages |
Abstract
A trend toward reduction in symptomatic RP among patients taking ACEIs during RT for NSCLC was not statistically significant on univariate or multivariate analyses, although certain subgroups may benefit from use (ie, male patients and those receiving low MLD). The evidence at this point is insufficient to establish whether the use of ACEIs does or does not reduce the risk of RP.
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
Hongmei PhD, Zhongxing MD, Yan MD, Ting MD, Quynh-Nhu MD, Lawrence B. MS, Michael MD, Kathryn A. MD, Daniel R. MD,